Cancer Cytogenetics

Methods and Protocols

Edited by

Thomas S.K. Wan

Haematology Division, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China

Humana Press
Preface

The discovery of the Philadelphia chromosome in 1960 ushered the field of cancer cytogenetics study into a new era. The development of fluorescence in situ hybridization (FISH) in 1980 helped to overcome many of the drawbacks in the assessment of genetic alterations in cancer cells by karyotyping. Subsequent methodological advances in molecular cytogenetics that were initiated in the early 1990s based on the principle of FISH have greatly enhanced the efficiency and accuracy of karyotype analysis by marrying conventional cytogenetics with molecular technologies. All of these molecular cytogenetic techniques add colors to the monotonous world of conventional chromosome banding. Currently, both karyotyping and FISH studies have emerged as indispensable tools for both basic and clinical research, which parallel their clinical diagnostic application in leukemia and cancers. The development, current utilization, detailed hands-on protocols, data interpretation, and technical pitfalls of these approaches used for cancer diagnosis and research will be included in this volume of book.

This volume Cancer Cytogenetics: Methods and Protocols of the Springer Methods in Molecular Biology series provides the readers with detailed protocols covering the main cancer cytogenetics techniques needed for clinical utilization and research purposes. Updated reviews on the recurrent chromosomal abnormalities in hematological malignancies provide an excellent, helpful benchmarking guide for cytogenetics data interpretation and specific malignant diseases correlation. All chapters were precisely written by professionally experienced cytogeneticists and/or pathologists working proactively in this specialized field. I have been very fortunate to have gathered a group of 52 experts from 15 countries or cities, including Australia, Canada, China, France, Germany, Hong Kong, Italy, Korea, the Netherlands, Poland, Russia, Singapore, Thailand, the United Kingdom, and the United States of America, in a short period of time to share their experiences empathetically and interactively. Although the circle of cancer cytogeneticists is relatively small, its task is notably significant, fostering worldwide contribution and collaboration. I would like to thank all of them for their generous contributions to this volume of book. In addition to the step-by-step description of every technique, much emphasis is placed on the pitfalls that accompany all testing procedures.

This book is intended for use by the novice in cytogenetics, providing helpful guiding protocols to them as well as deeper insights to those who are already engaged in the field, yet looking for some technical hints.

I am grateful to all colleagues in Cytogenetics Laboratory, Division of Haematology, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, under whose auspices this book was written. I would also like to thank Professor Ka-Fai To and Professor Margaret H. L. Ng for their continued encouragement. Last but not the least, I wish to express my thankful indebtedness to my wife, Mary, and my two sons, Conan and Eden, for their support and patience.

Hong Kong, China     Thomas S.K. Wan, PhD, FRCPath, FFSc(RCPA)
## Contents

*Preface* .................................................. vii  
*Contributors* ........................................... ix  

1 Cancer Cytogenetics: An Introduction ................................................................. 1  
   *Thomas S.K. Wan*  

2 Chromosome Preparation for Myeloid Malignancies .............................................. 11  
   *Eleanor K.C. Hui, Thomas S.K. Wan, and Margaret H.L. Ng*  

3 Chromosome Preparation for Acute Lymphoblastic Leukemia .................................. 19  
   *Mary Shago*  

4 Chromosome Preparation for Chronic Lymphoid Malignancies ................................ 33  
   *Dorota Koczkodaj and Agata A. Filip*  

5 Cyto genetic Harvesting of Cancer Cells and Cell Lines ...................................... 43  
   *Roderick A.F. MacLeod, Maren E. Kaufmann, and Hans G. Drexler*  

6 Chromosome Bandings ......................................................................................... 59  
   *Huifang Huang and Jiadi Chen*  

7 Chromosome Recognition ..................................................................................... 67  
   *Thomas S.K. Wan, Eleanor K.C. Hui, and Margaret H.L. Ng*  

8 Applications of Fluorescence In Situ Hybridization Technology in Malignancies ................................. 75  
   *Montakarn Tansatit*  

9 Fluorescence In Situ Hybridization Probe Preparation ........................................ 91  
   *Doron Tolomeo, Roscoe R. Stanyon, and Mariano Rocchi*  

10 Fluorescence In Situ Hybridization Probe Validation for Clinical Use ..................... 101  
   *Jun Gu, Janice L. Smith, and Patricia K. Dowling*  

11 Fluorescence In Situ Hybridization on Tissue Sections ....................................... 119  
   *Alvin S.T. Lim and Tse Hui Lim*  

12 Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma ................................................................. 127  
   *Sarah Moore, Jeffrey M. Suttle, and Mario Nicola*  

13 Quantitative Fluorescence In Situ Hybridization (QFISH) ..................................... 143  
   *Ivan Y. Iourov*  

14 High Resolution Fiber-Fluorescence In Situ Hybridization .................................. 151  
   *Christine J. Ye and Henry H. Heng*  

15 Array-Based Comparative Genomic Hybridization (aCGH) .................................... 167  
   *Chengsheng Zhang, Eliza Cerveira, Mallory Romanovitch, and Qibui Zhu*  

16 Multicolor Karyotyping and Fluorescence In Situ Hybridization-Banding (MCB/mBAND) .......................................................... 181  
   *Thomas Liehr, Moneeb A.K. Othman, and Katharina Rittscher*
Contents

17 Cytogenetics for Biological Dosimetry .......................................................... 189
   Michelle Ricoul, Tamizh Gnana-Sekaran, Laure Piqueret-Stephan, and Laure Sabatier

18 Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes ........... 209
   Menghan Wall

19 Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia .............. 223
   John J. Yang, Tae Sung Park, and Thomas S.K. Wan

20 Recurrent Cytogenetic Abnormalities in Myeloproliferative Neoplasms
   and Chronic Myeloid Leukemia ................................................................. 247
   John Swansbury

21 Recurrent Cytogenetic Abnormalities in Acute Lymphoblastic Leukemia .... 257
   Mary Shago

22 Recurrent Cytogenetic Abnormalities in Non-Hodgkin’s Lymphoma
   and Chronic Lymphocytic Leukemia .......................................................... 279
   Edmond S.K. Ma

23 Recurrent Cytogenetic Abnormalities in Multiple Myeloma ..................... 295
   Nelson Chun Ngai Chan and Natalie Pui Ha Chan

24 Cytogenetic Nomenclature and Reporting .................................................. 303
   Marian Stevens-Kroef, Annet Simons, Katrina Rack, and Rosalind J. Hastings

25 Cytogenetic Resources and Information ..................................................... 311
   Etienne De Braekeleer, Jean-Loup Huret, Hussain Mossafia, and Philippe Dessen

Index .................................................................................................................. 333
Contributors

ETIENNE DE BRAEKELEER • Haematological Cancer Genetics and Stem Cell Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
ELIZA CERVEIRA • The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
NELSON CHUN NGAI CHAN • Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Shatin, Hong Kong, China
NATALIE PUI HA CHAN • Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Shatin, Hong Kong, China
JIADI CHEN • Fujian Institute of Hematology, Fujian Medical University Affiliated Union Hospital, Fuzhou, People’s Republic of China
PHILIPPE DESSEN • UMR 1170 INSERM, Gustave Roussy, Villejuif, France
PATRICIA K. DOWLING • Cytogenetics, Pathline-Emerge Pathology Services, Ramsey, NJ, USA
HANS G. DREXLER • Department of Human and Animal Cell Lines, German Collection of Microorganisms and Cell Cultures, Leibniz Institute – DSMZ, Braunschweig, Germany
AGATA A. FILIP • Department of Cancer Genetics, Medical University of Lublin, Lublin, Poland
TAMIZH GNANA-SEKARAN • PROCyTOX Commissariat à l’Energie Atomique et aux Énergies Alternatives (CEA), Fontenay-aux-Roses and Université Paris-Saclay, Fontenay-aux-Roses Cedex, France
JUN GU • Cytogenetic Technology Program, School of Health Professions, UT MD Anderson Cancer Center, Houston, TX, USA
ROSALIND J. HASTINGS • Cytogenetic External Quality Assessment, Women’s Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
HENRY H. HENG • Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA; Karmanos Cancer Institute, Detroit, MI, USA
HUIFANG HUANG • Central Laboratory, Fujian Medical University Affiliated Union Hospital, Fuzhou, People’s Republic of China
ELEANOR K.C. HUI • Haematology Division, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Shatin, Hong Kong, China
JEAN-LOUP HURET • Medical Genetics, Department of Medical Information, University Hospital, Poitiers, France
IVAN Y. IOUROV • Mental Health Research Center, Moscow, Russia; Separated Structural Unit “Clinical Research Institute of Pediatrics” named after Y.E. Veltishev, Russian National Research Medical University named after N.I. Pirogov, Ministry of Health of Russian Federation, Moscow, Russia; Moscow State University of Psychology and Education, Moscow, Russia
MAREN E. KAUFMANN • Department of Human and Animal Cell Lines, German Collection of Microorganisms and Cell Cultures, Leibniz Institute – DSMZ, Braunschweig, Germany
DOROTA KOCZKODAJ • Department of Cancer Genetics, Medical University of Lublin, Lublin, Poland
THOMAS LIEHR • Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany
ALVIN S.T. LIM • Cytogenetics Laboratory, Department of Molecular Pathology, Singapore General Hospital, Singapore, Singapore
TSE HUI LIM • Cytogenetics Laboratory, Department of Molecular Pathology, Singapore General Hospital, Singapore, Singapore
EDMOND S.K. MA • Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong, China
RODERICK A.F. MACLEOD • Department of Human and Animal Cell Lines, German Collection of Microorganisms and Cell Cultures, Leibniz Institute – DSMZ, Braunschweig, Germany
SARAH MOORE • Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia
HOSSEIN MOSSAFA • Laboratoire CERBA, Saint Ouen l’Aumone, France
MARGARET H.L. NG • Haematology Division, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
MARIO NICOLA • Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
MONEEB A.K. OTMAN • Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany
TAE SUNG PARK • Department of Laboratory Medicine, School of Medicine, Kyung Hee University, Seoul, South Korea
LAURE PIQUERET-STEPHAN • PROCyTOX Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses and Université Paris-Saclay, Fontenay-aux-Roses Cedex, France
KATRINA RACK • Cytogenetic External Quality Assessment, Women’s Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
MICHELLE RICOUL • PROCyTOX Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses and Université Paris-Saclay, Fontenay-aux-Roses Cedex, France
KATHARINA RITTSCHER • Jena University Hospital, Institute of Human Genetics, Friedrich Schiller University, Jena, Germany
MARIANO ROCCHI • Department of Biology, University of Bari, Bari, Italy
MALLORY ROMANOVITCH • The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
LAURE SABATIER • PROCyTOX Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux-Roses and Université Paris-Saclay, Fontenay-aux-Roses Cedex, France
MARY SHAGO • Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
ANNET SIMONS • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
JANICE L. SMITH • Cytogenetics/FISH Division, Baylor Genetics Laboratories, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
ROSCOE R. STANYON • Laboratory of Anthropology, Department of Animal Biology and Genetics, University of Florence, Florence, Italy
MARIAN STEVENS-KROEF • Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
JEFFREY M. SUTTLE • Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia
JOHN SWANSBURY • Clinical Cytogenetics Laboratory, The Royal Marsden Hospital, Sutton, Surrey, UK
MONTAKARN TANSATIT • Unit of Medical Genetics, Medical Cytogenetics Laboratory, Department of Anatomy, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
DORON TOLOMEO • Department of Biology, University of Bari, Bari, Italy
MEAGHAN WALL • Victorian Cancer Cytogenetics Service, St. Vincent’s Hospital, Melbourne, Australia; Department of Medicine, St. Vincent’s Hospital, The University of Melbourne, Melbourne, Australia
THOMAS S.K. WAN • Haematology Division, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Shatin, China
JOHN J. YANG • Department of Laboratory Medicine, School of Medicine, Kyung Hee University, Seoul, South Korea
CHRISTINE J. YE • The Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
CHENGSHENG ZHANG • The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA
QIHUI ZHU • The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA